| |
Join BioIVT for an insightful webinar on the field of psychedelics including their potential to treat disorders, challenges for drug development, pharmacology, mode of action, and in vitro ADME properties.
Register Now >> 
|
|
Today’s Big NewsDec 2, 2024 |
| By Nick Paul Taylor Novartis is paying $1 billion up front for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping the biotech bounce quickly back from disappointing data on another program. |
|
|
|
By Nick Paul Taylor The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75% drop in the biotech’s share price. Applied said the complete response letter cited “deficiencies in the clinical application” but it plans to reapply or appeal. |
By Gabrielle Masson Cancer-focused Alligator Bioscience is clamping down on costs, laying off 70% of its team in efforts to save around $6 million every year. |
By Zoey Becker Along with the company's new data drop at the European Society for Medical Oncology Asia Congress, Merus also secured a partner for a separate candidate that's in line for an upcoming FDA decision. |
By Joseph Keenan Belgium mRNA specialist Quantoom Biosciences and biologics manufacturing specialist Univercells inked a partnership deal with the Oswaldo Cruz Foundation (Fiocruz) in a move aimed at expanding the development and production of RNA-based vaccines and therapies in Brazil and beyond. |
By Ben Adams Unless you have been living under a rock, you’ll know that anti-obesity GLP-1 drugs are the next big thing in pharma, with megablockbuster sales in a market that could be worth $126 billion by 2030 just on the horizon. |
By Heather Landi,Susan Kreimer Meet our 2024 Women of Influence. Each of the 10 women profiled this year is playing a major role in driving the industry forward. |
By Kevin Dunleavy The FDA is investigating reports of patients developing blood cancer after receiving bluebird bio’s gene therapy Skysona and is evaluating the need for “further regulatory action,” the U.S. agency said last week. The FDA notification came seven weeks after the New England Journal of Medicine (NEJM) published a report that seven of 67 children who received Skysona during clinical trials had developed blood cancer. |
By Fraiser Kansteiner Sanofi is laying out roughly 1 billion euros ($1.04 billion) to establish a new production base in the Beijing Economic and Technological Development Zone. The new manufacturing site, which will become Sanofi’s fourth in China, is being designed to beef up local end-to-end insulin production. |
By Conor Hale GE HealthCare unveiled a new mammography system with AI features aimed at easing the pressures from a shortage of trained technologists. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
Whitepaper We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
Whitepaper This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
